Insilico Medicine Lilly Deal Grants Exclusive Worldwide License Across Multi-Target AI Discovery Portfolio

Insilico Medicine's Pharma.AI platform is the centerpiece of a new multi-program drug discovery collaboration with Eli Lilly and Company (NYSE: LLY) that could be worth up to approximately USD 2.75 billion. Under the agreement announced March 29, 2026, Lilly receives an exclusive worldwide license for the development, manufacturing, and commercialization of novel oral therapeutics currently in preclinical development across multiple therapeutic areas. Insilico (HKEX: 3696) is eligible to receive a USD 115 million upfront payment, development, regulatory, and commercial milestones, and tiered royalties on future net sales.

The deal is structured around two components. The first grants Lilly exclusive global rights to an existing portfolio of preclinical oral small molecule programs for undisclosed indications. The second establishes a joint research effort in which Lilly selects targets and Insilico deploys its AI discovery engine to generate and optimize candidates against those targets. Lilly assumes responsibility for all downstream clinical development, regulatory filings, manufacturing, and commercialization. Specific therapeutic areas, target identities, and the number of programs covered have not been disclosed.

Deal context

Pharma.AI comprises three integrated modules. PandaOmics is a target discovery engine that mines multi-omics datasets — genomics, transcriptomics, proteomics, and pathway-level analyses — using deep learning and natural language processing to identify and prioritize druggable targets. Chemistry42 is a generative chemistry engine that uses deep generative models and reinforcement learning to design novel small molecules de novo, optimizing simultaneously for potency, selectivity, synthesizability, and drug-like properties rather than screening existing compound libraries. InClinico applies machine learning trained on historical clinical trial data to predict the probability of success at each clinical phase, informing portfolio-level go/no-go decisions.

The integration of these three modules distinguishes the platform from competitors that typically address only one segment of the discovery workflow. Recursion Pharmaceuticals (NASDAQ: RXRX) focuses on phenotypic screening and cellular imaging, Schrödinger (NASDAQ: SDGR) specializes in physics-based molecular simulation, and Exscientia (now acquired by Recursion) concentrated on AI-driven molecule optimization. Pharma.AI spans target identification through molecule generation to clinical prediction in a single suite. In this collaboration, Lilly is not bringing pre-defined targets to a molecule-design tool; it is accessing a system described by Insilico as capable of proposing novel biology, generating novel chemistry, and estimating clinical viability within one workflow.

The platform's clinical validation rests primarily on ISM001-055, a small molecule inhibitor of an undisclosed fibrosis target developed for idiopathic pulmonary fibrosis. Insilico advanced ISM001-055 from AI-driven target discovery through molecule design and into Phase II clinical trials, making it among the first wholly AI-discovered and AI-designed drugs to reach human testing. That program is not part of the Lilly collaboration but serves as proof-of-concept that the platform can produce candidates suitable for clinical development.

All programs covered under the Lilly agreement are at the discovery or preclinical stage. No specific drug candidates, clinical trial identifiers, or regulatory designations have been disclosed for any asset arising from this collaboration. The milestone structure — with a total potential value of approximately USD 2.75 billion inclusive of the upfront payment — implies the deal covers multiple distinct target programs, though the exact number has not been specified. Tiered royalty rates were not disclosed.

How the Insilico Medicine Lilly collaboration fits each company's pipeline strategy

For Lilly, the AI drug discovery partnership adds a computational discovery capability that complements its internal research infrastructure across therapeutic areas including cardiometabolic disease, oncology, immunology, and neuroscience. Andrew Adams, Lilly's Group Vice President of Molecule Discovery, characterized the arrangement as enabling exploration of novel mechanisms and acceleration of candidate identification across multiple disease areas. The deal allows Lilly to deploy generative AI drug development tools at scale without building an equivalent platform internally, effectively outsourcing the earliest and most attrition-prone phase of drug discovery to a specialized AI engine.

For Insilico, the Lilly AI pharma collaboration represents the largest disclosed external partnership for the Pharma.AI platform and arrives less than four months after the company listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025. The USD 115 million upfront payment provides non-dilutive capital to a company that has been investing in both its internal pipeline — spanning fibrosis, oncology, immunology, pain, and obesity — and in extending the platform's reach into adjacent industries such as advanced materials and agriculture. The Insilico Medicine R&D deal validates the commercial applicability of its end-to-end AI suite at a scale commensurate with large pharma discovery budgets.

The collaboration does not appear to restrict Insilico from entering similar platform-access arrangements with other pharmaceutical companies, as the exclusive license pertains to the therapeutic programs and molecules generated under the deal rather than to the underlying Pharma.AI technology itself. Insilico retains ownership of its platform intellectual property. No equity investment by Lilly in Insilico was disclosed as part of the transaction.

---

Spot something wrong? Report an issue with this article